Bejelentkezés Regisztrálj ingyen

Inhibrx Beta

Mi az Inhibrx Beta?

A Beta az Inhibrx, Inc. - 3.09

Mi a Beta meghatározása?



A BETA azt jelzi, hogy az állomány több-kevésbé volatilis, mint a piac egésze. Az 1-nél kevesebb béta azt jelzi, hogy az állomány kevésbé ingadozó, mint a piac, míg az 1-nél nagyobb béta azt jelzi, hogy az állomány volatilisabb. A volatilitást az átlag körüli ár ingadozásaként méri.

Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.

Beta a Health Care szektor a NASDAQ-on cégekben a Inhibrx -hoz képest

Mit csinál Inhibrx?

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

beta -hoz hasonló cégek Inhibrx